Another investigation into the expression and potential clinical utility of CB1 and CB2 in chronic lymphocytic leukemia (CLL) patients found that high CB1 expression (as measured via mRNA levels) was correlated with poor outcomes, and cultures of patient cells and normal cell controls from healthy patients showed decreased viability in response to cannabinoid treatment (primarily synthetic). The gene discussed is CNR1; the disease is B-cell chronic lymphocytic leukemia.